Post-dural puncture headache (PDPH) is a well-recognized and potentially serious complication of subarachnoid block. While advancements in spinal needle design have reduced its incidence in recent years, PDPH still affects a notable percentage of post-partum patients undergoing spinal anaesthesia, with rates ranging from 0.5% to 2%. Factors such as female gender, pregnancy, young age, low body mass index, dilutional anemia, and the preference for neuraxial anaesthesia during caesarean section (CS) increase the vulnerability of obstetric patients to PDPH. Therefore, managing this complication is critically important in obstetric anaesthesia. The exact cause of PDPH remains unclear, but there is substantial evidence suggesting that it stems from reduced cerebrospinal fluid (CSF) pressure due to continuous leakage through a dural tear, which exceeds the rate of CSF production. This imbalance can lead to PDPH, as even a modest loss of CSF volume (as little as 10%) can trigger traction on pain-sensitive intracranial structures when in an upright position, compounded by reflexive vasodilation. Various treatment strategies have been proposed, typically including bed rest in a supine position, fluid therapy, analgesics, and medications such as sumatriptan and caffeine. Dexmedetomidine (DEX) is a highly specific agonist of α2-adrenoreceptors known for inducing cooperative sedation, anxiolysis, and analgesia while minimizing respiratory depression. Additionally, it has been shown to mitigate the stress and inflammatory response triggered by surgical and anaesthetic procedures. Activation of α2-receptors in the substantia gelatinosa of the dorsal horn suppresses the firing of nociceptive neurons and inhibits the release of substance P. Furthermore, stimulation of these receptors in the locus coeruleus, a key modulator of nociceptive transmission, interrupts the transmission of pain signals, resulting in analgesia. Dexmedetomidine has been administered via intranasal and inhalational routes for various purposes, including premedication, sedation, and post-operative analgesia. Lidocaine nebulized is a novel method used recently for PDPH. Intranasal lidocaine can offer sphenopalatine ganglion block which can facilitate acute pain reduction in PDPH.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
114
nebulization of 4 mL 0.9% saline twice daily
nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
bilateral nebulization (60 mg) using a mucosal atomization device twice daily
Pain severity
Visual analogue scale from 0 to ten . 0 = no pain. 1-3=mild pain, 4-6= moderate. 7- 10= severe un imaginable pain
Time frame: at enrollment,1,3,6, 12, 24,36, 48, 72 hours
leybecker classification
degree of headache ... \<2 = mild pain.. \> 2= severe pain
Time frame: At enrollment, 1,3,6, 12,24,36,48, 73 hours
Transcranial doppler
Measuring mean flow velocity
Time frame: at enrollment, 24,48,72 hours
NEED for epidural blood patch
Visual analogue scale from 0 to ten . 0 = no pain. 1-3=mild pain, 4-6= moderate. 7- 10= severe un imaginable pain. Epidural blood patch if visual analogue scale more than or equal 4.
Time frame: 72 hours during the invesigation
Procedural related complications
hypotension, bradycardia
Time frame: 72 hours from the procedure
persistent symptoms
Tinnitus, photophobia, orthostatic hypotension
Time frame: one week after hospital discharge
transcranial doppler
pulsatality index
Time frame: at enrollment, 24,48,72 hours
transcranial doppler
resisitive index
Time frame: at enrollment, 24,48,72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.